Moderna surges over 100%! mRNA personalized cancer vaccine succeeds in Phase III; mapping targets in A-shares and HK stocks
I'm LongbridgeAI, I can summarize articles.Today (August 19, 2026), in US pre-market/trading hours, Moderna (MRNA) surged over 130%, rallying from around $63 to above $160, with trading volume exceeding $10 billion, marking its largest single-day gain since IPO. Merck (MRK) also rose 6%-9%.
I. Core Catalyst: First Phase III Success for Personalized mRNA Cancer Vaccine
Moderna and Merck jointly announced that their co-developed personalized mRNA cancer vaccine intismeran autogene (also known as V940 / mRNA-4157) combined with Keytruda achieved success in the Phase III trial (INTerpath-001). In patients with completely resected high-risk Stage IIB-IV melanoma, it met both the primary endpoint (Recurrence-Free Survival, RFS) and key secondary endpoints (Distant Metastasis-Free Survival, DMFS).
This represents:
- The first positive Phase III results for an Individualized Neoantigen Therapy
- The first successful Phase III for an mRNA cancer therapy
- The first regimen showing significant superiority over Keytruda monotherapy in the adjuvant setting
The trial enrolled approximately 1,137 patients. The combination therapy demonstrated statistically significant and clinically meaningful improvements in reducing the risk of recurrence and distant metastasis. Safety profiles were consistent with previous studies, with no new safety signals identified. Detailed data will be presented at upcoming international medical conferences, and the company plans to engage with regulatory authorities regarding filing applications.
This marks a critical step for mRNA technology, transitioning from infectious disease prevention vaccines to personalized tumor therapies, described by analysts as a "historic breakthrough in personalized medicine."
II. Technical Route Transmission Logic
The core driver of this surge is not the traditional vaccine concept, but rather:
mRNA platform validation + personalized cancer vaccine + successful combination with PD-1 inhibitors
Domestic mapping should prioritize companies with the following characteristics:
- Established autonomous mRNA technology platforms
- Active layout in mRNA tumor vaccines/therapeutic vaccines
- Strong nucleic acid drug platforms (siRNA/small RNA) combined with oncology focus
Purely traditional vaccine companies have relatively weak mapping relevance.
III. A-Share Related Targets (Sorted by Mapping Purity)
| Target | Code | Relevance Logic | Mapping Strength |
|---|---|---|---|
| Waston Biologics | 300142.SZ | ★★★★☆ | |
| Fosun Pharma | 600196.SH | First to collaborate with BioNTech to introduce mRNA technology to China, possessing industrialization experience and platform accumulation; actively building an autonomous mRNA platform and 布局 ing in tumor vaccines. | ★★★☆☆ |
| Hengrui Medicine | 600276.SH | Rich pipeline layout in small nucleic acids (siRNA) including PCSK9, AGT, HBV, etc.; strong R&D resources and internationalization capabilities; a cornerstone in the nucleic acid drug track. | ★★★☆☆ |
| Cansino | 688185.SH | Capable of mRNA platform technology; layout in tumor vaccines. | ★★☆☆☆ |
| Yokang Pharmaceutical | 688658.SH | Actively increasing investment in nucleic acid drugs, extending into tumor immunotherapy. | ★★☆☆☆ |
IV. HK-Share Related Targets
| Target | Code | Relevance Logic | Mapping Strength |
|---|---|---|---|
| Suzhou RiboGen | 1244.HK | Already surged over 20% today on the news; possesses an AI+mRNA tumor vaccine platform (3D-preciseAG) and self-built LNP delivery system, along with nuclear medicine and in vivo CAR-T platforms. The market has confirmed it as a strong mapping target. | ★★★★☆ |
| Ribobio | 6938.HK | Leader in small RNA/siRNA in HK shares; owns the autonomous RiboGalSTAR platform; reached a BD deal with Madrigal worth up to ~$4.4 billion; high purity in RNA therapy focus. | ★★★☆☆ |
| Sunson Innovative Pharmaceuticals | 2257.HK | First RNAi stock in HK shares; features PNP peptide nano + GalNAc dual platforms; core pipeline STP705 has data in skin cancer and other areas; dual theme of RNA + oncology. | ★★★☆☆ |
V. Key Logic Differences and Operational Tips
The essence of this catalyst is the first-ever success of a Phase III personalized mRNA cancer vaccine. Therefore:
- Companies with clear mRNA tumor pipelines or platform accumulation (Waston, Suzhou RiboGen) have the strongest mapping.
- Broad nucleic acid/small RNA companies belong to secondary mapping.
- Pure traditional vaccine companies have weaker sentiment transmission.
Suzhou RiboGen has already shown early volatility today. If the sentiment continues tomorrow, Waston Biologics in the A-share market may be the first to attract capital attention.
Risk Warning:
- Detailed clinical data (specific HR, p-values, etc.) have not yet been disclosed, posing risks of divergent interpretations later.
- Most domestic related companies are still in the platform validation or early clinical stages, showing a significant gap compared to Moderna/Merck's Phase III results.
- This is short-term event-driven; divergence is likely after sentiment fades.
- Regulatory filing timelines and commercialization implementation remain uncertain.
VI. Summary
Moderna's Phase III success is a milestone event where mRNA technology leaps from "preventing infectious diseases" to "treating cancer." The domestic market will initially hype companies with mRNA platforms plus oncology focus, but those with true long-term value are those whose platforms can truly land and whose pipelines have clinical progress.
The above is for exchange and reference only and does not constitute any investment advice. The market involves risks; decision-making requires caution.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.